Phase 2 Clinical Trial Progress Update
CRISM Therapeutics Corporation has announced significant progress in its Phase 2 clinical trial for irinotecan ChemoSeed® in glioblastoma patients, with all manufacturing, quality, regulatory, and start-up activities completed and site activation advanced. A Site Initiation Visit is planned for late July, after which patient recruitment and dosing updates will be provided. The company confirms it is fully funded to complete Part 1 of the trial and is well-positioned to commence Part 2.
Select text to share a quote on X · sign in to keep highlights & notes in your CRTX notes
596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.
CRISM Therapeutics Corporation
("CRISM", "CRISM Therapeutics" or the "Company")
Phase 2 Clinical Trial Progress Update
CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, provides an update on its Phase 2 clinical trial of irinotecan ChemoSeed® in patients with glioblastoma.
The Company confirms that all product manufacturing, quality, regulatory and study start-up activities required for patient treatment have been completed and that site activation is at an advanced stage. Multiple clinical support departments have completed their individual assessments and sign-off procedures, and a Site Initiation Visit ("SIV"), the final procedural step before the site can be activated for patient recruitment, is planned for late July. This represents significant progress and the Company will provide further updates regarding patient recruitment and dosing following the SIV.
The Company is fully funded to complete Part 1 of the trial and is well positioned to initiate Part 2 on completion. The Board looks forward to providing shareholders with further updates regarding the trial and the clinical development of ChemoSeed in due course.
The Company's LEI is 213800XFW6MKVCHHPW88.
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.